GLP-1RAs significantly reduce major cardiovascular events, mortality, and other clinically significant complications in ...
These findings, published in JAMA Network Open, come from a large cohort study by Maxime Beydon and colleagues from Sorbonne ...
Altogether, the 4 newest IgAN drugs -- sparsentan, targeted-release budesonide, iptacopan, and atrasentan -- were prescribed to less than 5% of patients in a 2024-2025 US database. A new study ...
Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results